New imaging technology for diagnosing retinopathy of prematurity in infants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop and utilize a novel imaging technology called HH-SECTR to visualize and quantify diagnostic features of retinopathy of prematurity (ROP) in preterm infants. The imaging will be conducted weekly alongside standard ROP screenings without altering patient management. The goal is to identify vascular and structural disease features that are not currently accessible through standard examination methods, thereby enhancing clinical decision-making. The study will involve imaging both eyes of eligible infants until they reach 45 weeks or require therapeutic intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Preterm male and female infants born at 24-34 weeks gestational age and weighing \<1500g at birth

Exclusion Criteria:

* Infants surgically treated for ROP
* Infants with significant health concern that would preclude noninvasive retinal imaging as noted by the primary inpatient team

Where it's running

• Vanderbilt University Medical Center
  Nashville, Tennessee, United States Recruiting

Study contacts

• Study coordinator: Irina De la Huerta, MD, PhD
• Email: CTU.ROP@vumc.org
• Phone: 615-936-2020

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging retinal structure in premature babies to guide care

  This study tests whether bedside ultra-widefield eye imaging can better guide treatment decisions for retinopathy of prematurity in preterm infants.

  Recruiting Duke University · Durham, North Carolina and 1 other locations · NCT07738874

• Does early red blood cell transfusion affect complications and neurodevelopment in premature infants?

  This study tests whether giving blood transfusions in the first month of life in premature babies is linked to early complications like ROP, NEC, BPD, IVH, and to later neurodevelopmental outcomes.

  Recruiting Clinical Hospital Center Rijeka · Rijeka, Primorje-Gorski Kotar County · NCT07123948

• Testing FLQ-101 for retinopathy of prematurity in very premature newborns

  This will test whether giving FLQ-101 to very premature babies (born at 26+0 to 27+6 weeks and weighing ≥650 g) is safe and produces the expected drug effects in their bodies.

  Recruiting Phase 1 Feliqs INC. · Austin, Texas · NCT07093255

• Low-dose Conbercept treatment for Retinopathy of Prematurity

  This study is testing if a low-dose eye treatment called Conbercept can help preterm infants with Retinopathy of Prematurity feel better and improve their vision.

  Recruiting at 3 sites Xijing Hospital · Xi'an, Shaanxi and 2 other locations · NCT06717412

• Evaluating pain relief methods during eye exams for premature infants

  This study is testing two different ways to hold premature infants during eye exams to see which one helps reduce their pain better.

  Recruiting Ege University · Izmir, Menemen · NCT06694103

• Incidence of hypoxia during intravitreal ranibizumab injections for retinopathy of prematurity under topical anesthesia

  This study looks at how often and how severely babies with retinopathy of prematurity experience low oxygen levels during bedside eye injections with topical anesthesia.

  Recruiting Minia University · Buraidah · NCT07701759

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.